CC
DNA icon

Centiva Capital’s Ginkgo Bioworks DNA Stock Holding History

Centiva Capital’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-18,861
Closed -$252K – 2265
2024
Q2 		$252K Buy
+18,861
New +$563K 0.01% 1557
2023
Q4 		– Sell
-750
Closed -$54.3K – 1906
2023
Q3 		$54.3K Buy
+750
New +$60K ﹤0.01% 1595
2022
Q3 		– Sell
-1,036
Closed -$99K – 1573
2022
Q2 		$99K Buy
+1,036
New +$126K 0.01% 1430
2022
Q1 		– Hold
0
– – – 1692
2021
Q4 		– Hold
0
– – – 1299

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $758M AUM 124.8% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $121B AUM 33.93% 1-Year Est. Return